Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Aegerion Pharmaceuticals, Inc. (AEGR): Will This Speculative Cholesterol Treatment Pay Off?

In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC. Even though the American Heart Association states that people with high LDL levels exceeding 200 mg/dL are twice as likely to develop coronary heart disease, only half of adults in the U.S. seek treatment, often leading to premature death.

This epidemic of high cholesterol levels across the nation is often associated with unhealthy diets and sedentary lifestyles, leading to the rising demand for cholesterol treatments from pharmaceutical companies. Let’s take a look at some of the more established and speculative products in the market today.

The party’s over for Pfizer and Merck

The past decade was primarily dominated by Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK), which respectively produced Lipitor (atorvastatin) and Zocor (simvastatin), two widely used high LDL cholesterol treatments. Both Lipitor and Zocor are statin treatments, which slow the liver’s ability to produce LDL. However, statin treatments can cause a wide array of side effects, including muscle pain, liver damage, digestive problems, rashes, elevated blood sugar levels, and neurological side effects.

Those side effects, some rarer than others, have been a major reason that many Americans avoid taking high LDL medications, especially since many high cholesterol cases can be controlled through an improved diet and frequent exercise. However, both Lipitor and Zocor have been shown to significantly lower high LDL cholesterol — by 57% and 47% (at their highest doses), respectively, making them viable options for high-risk patients.

Although Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) had a good run with these cholesterol drugs over the past decade, Lipitor’s patent protection expired in 2011, and Zocor’s expired in 2006. Since then, many generic high LDL statin treatments have hit the market, such as Watson Pharmaceuticals’ generic Lipitor and Teva Pharmaceuticals’ generic Zocor.

Non-statin alternatives

Due to the side effects of statin, there is a market for non-statin treatments. These include bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. Bile acid sequestrants bind cholesterol to bile acid, which is then removed in the stool. Fibrates enable the liver to absorb more fatty acids to increase the production of HDL (“good”) cholesterol. Cholesterol absorption inhibitors allow the intestine to directly absorb LDL cholesterol with very few side effects.

Although those treatments are all possible alternatives to statin treatments, they have not replicated the massive reduction of LDL cholesterol by directly targeting the liver’s production of LDL, as statins do. That’s where a new medication, Juxtapid (lomitapide), comes in.

Could Juxtapid be a game changer?

Juxtapid, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) only marketed drug, is the first of a new class of LDL treatments called microsomal triglyceride transfer protein (MTP) inhibitors, which can slow the assembly of very low-density LDLs in the liver. Juxtapid is currently only approved for patients with homozygous familial hypercholesterolemia (a rare inherited disorder) who are already taking statin medications. Yet, in those patients, Juxtapid reduced LDL by 40% to 50%.

In a clinical study, 28% of patients on Juxtapid had diarrhea, nausea, vomiting, and abdominal pain. However, those side effects are minimal compared to those caused by traditional statin treatments. Liver tests are also required for patients before and after treatments, since Juxtapid can cause liver problems, according to the FDA. Therefore, patients considering using Juxtapid are required to first enroll in a Juxtapid REMS (Risk Evaluation and Mitigation Strategy) program for liver testing.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.